Daniel Knowles, PA
Physician Assistant · Charleston, SCNPI 1972169373
Payments from drug & device makers
Across 367 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$897
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$740
- Pfizer$568
- E.r. Squibb & Sons, L.L.C.$503
- Novartis$469
- Amgen$378
- plus $4K from 34 others
What the payments were for
- Food & beverage$7,20999%
- Education$891%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 48 | $897 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 34 | $740 |
| Pfizer | 33 | $568 |
| E.r. Squibb & Sons, L.L.C. | 25 | $503 |
| Novartis | 33 | $469 |
| Amgen | 19 | $378 |
| Abbott | 7 | $366 |
| Merck | 22 | $359 |
| Boston Scientific | 9 | $290 |
| Esperion Therapeutics, Inc. | 15 | $262 |
| Biotronik Inc. | 6 | $250 |
| Scpharmaceuticals Inc. | 11 | $248 |
| Johnson & Johnson | 16 | $234 |
| AstraZeneca | 11 | $219 |
| Philips North America LLC | 4 | $205 |
| Kiniksa Pharmaceuticals, Ltd. | 8 | $142 |
| Sanofi-aventis U.S. LLC | 7 | $124 |
| Alnylam Pharmaceuticals Inc. | 7 | $122 |
| Novo Nordisk | 6 | $100 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $99 |
| Actelion Pharmaceuticals US, Inc. | 4 | $89 |
| Amarin Pharma, Inc. | 5 | $78 |
| Bridgebio Pharma, Inc. | 3 | $64 |
| United Therapeutics Corporation | 4 | $57 |
| Regeneron Healthcare Solutions, Inc. | 3 | $47 |
| Impulse Dynamics (USA) Inc. | 3 | $43 |
| BD | 1 | $42 |
| Bayer | 2 | $41 |
| Lilly USA, LLC | 3 | $40 |
| Medicomp Inc | 2 | $33 |
| Optinose US, Inc. | 2 | $26 |
| Nestle Healthcare Nutrition Inc. | 2 | $26 |
| Medtronic | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Edwards Lifesciences | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| GSK | 1 | $16 |
| Cvrx, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (5091) Amb Mon & Diag Und$133
- WATCHMAN FLX$130
- ELIQUIS$124
- AMPLATZER AMULET$120
- Edora 8 DR-T$107
- BioMonitor$107
- Rivacor 7 DR-T$107
- Acticor 7 VR-T DX$107
How this compares
$7,298 in reported general payments places this provider in the 90th percentile of 1,852 physician assistant providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 181 | $213,620 |
| EntrestoSacubitril/Valsartan | 58 | $65,346 |
| XareltoRivaroxaban | 48 | $64,456 |
| Repatha SureclickEvolocumab | 16 | $19,037 |
| JardianceEmpagliflozin | 17 | $17,968 |
| BrilintaTicagrelor | 15 | $10,509 |
| Repatha SyringeEvolocumab | 12 | $7,717 |
| Atorvastatin Calcium | 163 | $2,584 |
| Rosuvastatin Calcium | 133 | $2,419 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 66 | $2,398 |
| Metoprolol Succinate | 177 | $2,328 |
| Nebivolol Hcl | 29 | $1,721 |
| Bumetanide | 59 | $1,670 |
| Carvedilol | 167 | $1,484 |
| Bisoprolol Fumarate | 54 | $1,447 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $568 | $213,620181 claims |
| NovartisEntresto | $469 | $65,34658 claims |
| Johnson & JohnsonXarelto | $234 | $64,45648 claims |
| Boehringer IngelheimJardiance | $897 | $17,96817 claims |
| AstraZenecaBrilinta | $219 | $10,50915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,852 physician assistant providers in South Carolina.
Other physician assistant in Charleston
- Michael OvercashCharleston$210K
- Elizabeth HardingCharleston$28K
- Whitney PutillionCharleston$18K
- Corin JaynesCharleston$17K
- Karen ByrdCharleston$16K
- Colleen ManningCharleston$14K
- Kara GayCharleston$13K
- John RicheyCharleston$12K
- John HendrickCharleston$11K
- Keenan RosadoCharleston$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.